{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:04:47Z","timestamp":1793505887131,"version":"4.5.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Romosozumab treatment in women with postmenopausal osteoporosis increases bone formation while decreasing bone resorption, resulting in large BMD gains to reduce fracture risk within 1\u00a0yr. DXA-based 3D modeling of the hip was used to assess estimated changes in cortical and trabecular bone parameters and map the distribution of 3D changes in bone parameters over time in patients from 2 randomized controlled clinical trials: FRAME (romosozumab vs placebo followed by denosumab) and ARCH (romosozumab vs alendronate followed by alendronate). For each study, data from a subset of ~200 women per treatment group who had TH DXA scans at baseline and months 12 and 24 and had provided consent for future research were analyzed post hoc. 3D-SHAPER software v2.11 (3D-SHAPER Medical) was used to generate patient-specific 3D models from TH DXA scans. Percentage changes from baseline to months 12 and 24 in areal BMD (aBMD), integral volumetric BMD (vBMD), cortical thickness, cortical vBMD, cortical surface BMD (sBMD), and trabecular vBMD were evaluated. Data from 377 women from FRAME (placebo, 190; romosozumab, 187) and 368 women from ARCH (alendronate, 185; romosozumab, 183) with evaluable 3D assessments at baseline and months 12 and 24 were analyzed. At month 12, treatment with romosozumab vs placebo in FRAME and romosozumab vs alendronate in ARCH resulted in greater increases in aBMD, integral vBMD, cortical thickness, cortical vBMD, cortical sBMD, and trabecular vBMD (P\u2009&amp;lt;\u2009.05 for all). At month 24, cumulative gains in all parameters were greater in the romosozumab-to-denosumab vs placebo-to-denosumab sequence and romosozumab-to-alendronate vs alendronate-to-alendronate sequence (P\u2009&amp;lt;\u2009.05 for all). 3D-SHAPER analysis provides a novel technique for estimating changes in cortical and trabecular parameters from standard hip DXA images. These data add to the accumulating evidence that romosozumab improves hip bone density and structure, thereby contributing to the antifracture efficacy of the drug.<\/jats:p>","DOI":"10.1093\/jbmr\/zjae028","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T16:19:05Z","timestamp":1707754745000},"page":"473-483","source":"Crossref","is-referenced-by-count":25,"title":["3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate"],"prefix":"10.1093","volume":"39","author":[{"given":"E Michael","family":"Lewiecki","sequence":"first","affiliation":[{"name":"New Mexico Clinical Research & Osteoporosis Center , 300 Oak St NE, Albuquerque, NM 87106 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Betah","sequence":"additional","affiliation":[{"name":"Amgen Inc. , One Amgen Center Drive, Thousand Oaks, CA 91320 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Humbert","sequence":"additional","affiliation":[{"name":"3D-SHAPER Medical , Rambla de Catalunya, 53, 4-H, Eixample, 08007 Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Libanati","sequence":"additional","affiliation":[{"name":"UCB Pharma , All\u00e9e de la Recherche, 60, Brussels B-1070 , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Oates","sequence":"additional","affiliation":[{"name":"Amgen Inc. , One Amgen Center Drive, Thousand Oaks, CA 91320 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Shi","sequence":"additional","affiliation":[{"name":"Amgen Inc. , One Amgen Center Drive, Thousand Oaks, CA 91320 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Winzenrieth","sequence":"additional","affiliation":[{"name":"3D-SHAPER Medical , Rambla de Catalunya, 53, 4-H, Eixample, 08007 Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Division of Bone Diseases , University Hospital of Geneva, Geneva 1211 , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitoshi","family":"Omura","sequence":"additional","affiliation":[{"name":"Koenji Orthopedics Clinic , 4-29-2, Koenji minami, Suginami-ku, Tokyo, 166-0003 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"issue":"1","key":"2024050213183703400_ref1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev-bioeng-062117-121139","article-title":"Bone mechanical properties in healthy and diseased states","volume":"20","author":"Morgan","year":"2018","journal-title":"Annu Rev Biomed Eng"},{"issue":"6","key":"2024050213183703400_ref2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.berh.2009.09.008","article-title":"Quantifying the material and structural determinants of bone strength","volume":"23","author":"Bouxsein","year":"2009","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"2024050213183703400_ref3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jclinepi.2010.07.007","article-title":"Which fractures are most attributable to osteoporosis?","volume":"64","author":"Warriner","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"2024050213183703400_ref4","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"Johnell","year":"2006","journal-title":"Osteoporos Int"},{"key":"2024050213183703400_ref5","volume-title":"Medicare Cost of Osteoporotic Fractures \u20132021 Updated Report: The Clinical and Cost Burden of Fractures Associated with Osteoporosis","author":"Hansen","year":"2021"},{"issue":"3","key":"2024050213183703400_ref6","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/jbmr.1472","article-title":"Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures","volume":"27","author":"Austin","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2024050213183703400_ref7","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/jbmr.3427","article-title":"FRAME study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab","volume":"33","author":"Cosman","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2024050213183703400_ref8","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1007\/s00198-015-3179-x","article-title":"Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years","volume":"26","author":"Ferrari","year":"2015","journal-title":"Osteoporos Int"},{"issue":"10117","key":"2024050213183703400_ref9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"2024050213183703400_ref10","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial","volume":"60","author":"Saag","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"10102","key":"2024050213183703400_ref11","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"2024050213183703400_ref12","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.mayocp.2016.10.009","article-title":"Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial","volume":"92","author":"Cosman","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"2024050213183703400_ref13","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jbmr.3641","article-title":"Change in bone density and reduction in fracture risk: a meta-regression of published trials","volume":"34","author":"Bouxsein","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024050213183703400_ref14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/jbmr.2024","article-title":"Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab","volume":"29","author":"Keaveny","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024050213183703400_ref15","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00223-005-0070-3","article-title":"Structural analysis of trabecular bone of the proximal femur using multislice computed tomography: a comparison with dual x-ray absorptiometry for predicting biomechanical strength in vitro","volume":"78","author":"Bauer","year":"2006","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"2024050213183703400_ref16","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/jbmr.2033","article-title":"Microstructural failure mechanisms in the human proximal femur for sideways fall loading","volume":"29","author":"Nawathe","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024050213183703400_ref17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/jbmr.207","article-title":"Influence of vertical trabeculae on the compressive strength of the human vertebra","volume":"26","author":"Fields","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"S3","key":"2024050213183703400_ref18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00198-002-1345-4","article-title":"Bone strength and its determinants","volume":"14","author":"Ammann","year":"2003","journal-title":"Osteoporos Int"},{"issue":"Suppl 2","key":"2024050213183703400_ref19","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0020-1383(16)47003-8","article-title":"Bone mechanical properties and changes with osteoporosis","volume":"47","author":"Osterhoff","year":"2016","journal-title":"Injury"},{"issue":"1","key":"2024050213183703400_ref20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1749-6632.2009.05348.x","article-title":"Biomechanical computed tomography\u2014noninvasive bone strength analysis using clinical computed tomography scans","volume":"1192","author":"Keaveny","year":"2010","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"2024050213183703400_ref21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1109\/TMI.2016.2593346","article-title":"3D-DXA: assessing the femoral shape, the trabecular macrostructure and the cortex in 3D from DXA images","volume":"36","author":"Humbert","year":"2017","journal-title":"IEEE Trans Med Imaging"},{"issue":"4","key":"2024050213183703400_ref22","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1118\/1.4944501","article-title":"Technical note: cortical thickness and density estimation from clinical CT using a prior thickness-density relationship","volume":"43","author":"Humbert","year":"2016","journal-title":"Med Phys"},{"issue":"3","key":"2024050213183703400_ref23","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00198-020-05806-1","article-title":"Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modeling","volume":"32","author":"Winzenrieth","year":"2021","journal-title":"Osteoporos Int"},{"issue":"3","key":"2024050213183703400_ref24","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jocd.2021.11.007","article-title":"Abaloparatide effects on cortical volumetric BMD and estimated strength indices of hip subregions by 3D-DXA in women with postmenopausal osteoporosis","volume":"25","author":"Winzenrieth","year":"2022","journal-title":"J Clin Densitom"},{"issue":"4","key":"2024050213183703400_ref25","doi-asserted-by":"crossref","first-page":"e10612","DOI":"10.1002\/jbm4.10612","article-title":"Proximal femur responses to sequential therapy with abaloparatide followed by alendronate in postmenopausal women with osteoporosis by 3D modeling of hip dual-energy x-ray absorptiometry (DXA)","volume":"6","author":"Winzenrieth","year":"2022","journal-title":"JBMR Plus"},{"issue":"3","key":"2024050213183703400_ref26","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jocd.2018.11.004","article-title":"DXA-based 3D analysis of the cortical and trabecular bone of hip fracture postmenopausal women: a case-control study","volume":"23","author":"Humbert","year":"2020","journal-title":"J Clin Densitom"},{"issue":"5","key":"2024050213183703400_ref27","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"2024050213183703400_ref28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2024050213183703400_ref29","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study","volume":"33","author":"McClung","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"16","key":"2024050213183703400_ref30","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"2024050213183703400_ref31","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"2024050213183703400_ref32","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1002\/jbmr.4409","article-title":"Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-cCntrolled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk (ARCH) trial","volume":"36","author":"Brown","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2024050213183703400_ref33","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/jbmr.3735","article-title":"Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment","volume":"34","author":"Chavassieux","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024050213183703400_ref34","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jbmr.2932","article-title":"Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass","volume":"32","author":"Genant","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024050213183703400_ref35","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/jbmr.4465","article-title":"Romosozumab enhances vertebral bone structure in women with low bone density","volume":"37","author":"Poole","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2024050213183703400_ref36","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/jbmr.3176","article-title":"Greater gains in spine and hip strength for romosozumab compared with teriparatide in postmenopausal women with low bone mass","volume":"32","author":"Keaveny","year":"2017","journal-title":"J Bone Miner Res"},{"key":"2024050213183703400_ref37","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1111020","article-title":"2D-3D reconstruction of the proximal femur from DXA scans: evaluation of the 3D-Shaper software","volume":"11","author":"Dudle","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"issue":"3","key":"2024050213183703400_ref38","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.media.2010.01.003","article-title":"High resolution cortical bone thickness measurement from clinical CT data","volume":"14","author":"Treece","year":"2010","journal-title":"Med Image Anal"},{"issue":"1","key":"2024050213183703400_ref39","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/BF01623175","article-title":"Cross-calibration of liquid and solid QCT calibration standards: corrections to the UCSF normative data","volume":"3","author":"Faulkner","year":"1993","journal-title":"Osteoporos Int"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjae028\/57114779\/zjae028.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/39\/4\/473\/57372631\/zjae028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/39\/4\/473\/57372631\/zjae028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T09:19:59Z","timestamp":1714641599000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/39\/4\/473\/7608776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,2,15]]},"published-print":{"date-parts":[[2024,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjae028","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,2,15]]}}}